Vascular Biogenics is a biopharmaceutical company in Israel and the United States that focuses on developing therapeutics to treat cancer and immune-inflammatory diseases. They use gene and antibody-based technologies to target newly formed blood vessels and inhibit monocyte migration. They are currently in clinical trials for their lead product VB-111, which is aimed at treating recurrent ovarian cancer, glioblastoma, and colorectal cancer.